Treatment strategies for recurrent Clostridium difficile infection

Canadian Journal of Hospital Pharmacy

Volumn 66, Issue 6, 2013, Pages 361-368

  Leong, Christine ^a   Zelenitsky, Sheryl ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Fidaxomicin; Literature review; Metronidazole; Recurrent Clostridium difficile infection; Relapse; Vancomycin

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; PROBIOTIC AGENT; RIFAMPICIN; RIFAXIMIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COCHRANE LIBRARY; DRUG COST; DRUG TREATMENT FAILURE; EMBASE; FECES MICROFLORA; HUMAN; MEDLINE; NONHUMAN; PRACTICE GUIDELINE; RECURRENT INFECTION; REVIEW; TREATMENT DURATION;

EID: 84903772113     PISSN: 00084123     EISSN: 19202903     Source Type: Journal    
DOI: 10.4212/cjhp.v66i6.1301     Document Type: Review

References (54)

1. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-55.
2. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478-98.
3. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis. 2005;5(9):549-57. (Pubitemid 41196754)
4. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010;74(4):309-18.
5. Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M; Canadian Hospital Epidemiology Committee. Morbidity, morality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol. 2002;23(3):137-40. (Pubitemid 34246541)
6. Simor A, Bradley SF, Strausbaugh LJ, Crossley K, Nicolle LE; SHEA Long- Term-Care Committee. Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol. 2002;23(11):696-703. (Pubitemid 35315995)
7. Dubberke E. Clostridium difficile infection: the scope of the problem. J Hosp Med. 2012;7(Suppl 3):S1-4.
8. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN. Nosocomial Clostridium difficile colonisation and disease. Lancet. 1990; 336(8707):97-100. (Pubitemid 20222816)
9. Kasper AM, Nyazee HA, Yokoe DS, Mayer J, Mangino JE, Khan YM, et al.; Centers for Disease Control and Prevention Epicenters Program. A multicenter study of Clostirium difficile infection-related colectomy, 2000-2006. Infect Control Hosp Epidemiol. 2012;33(5):470-6.
10. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357(9251):189-93. (Pubitemid 32108091)
11. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40(11):1586-90. (Pubitemid 40720807)
12. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346(5):334-9.
13. Pepin J. Vancomycin for the treatment of Clostridium difficile infection: For whom is this expensive bullet really magic? Clin Infect Dis. 2008;46(10):1493-8. (Pubitemid 351706728)
14. MacCannell DR, Louie TJ, Gregson DB, Laverdiere M, Labbe AC, Laing F, et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from eastern and western Canada. J Clin Microbiol. 2006;44(6):2147-52. (Pubitemid 43902167)
15. Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171(5):466-72. (Pubitemid 39179608)
16. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442-9. (Pubitemid 41770165)
17. Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 2005;173(9):1037-41. (Pubitemid 41546690)
18. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluorquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254-60. (Pubitemid 41532667)
19. Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, et al. Health care-associated Clostiridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis. 2010;50(2):194-201.
20. Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol. 2007;102(12):2781-8. (Pubitemid 350179349)
21. Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, Johnson S. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect. 2007;55(6):495-501. (Pubitemid 350082477)
22. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis. 2008;47(1):56-62. (Pubitemid 351920588)
23. Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302-7. (Pubitemid 47101025)
24. Fernandez A, Anand G, Riedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol. 2004;38(5):414-8.
25. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet. 1983;2(8358):1043-6. (Pubitemid 14235361)
26. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis. 2002;35(6):690-6. (Pubitemid 35024729)
27. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986;27(10):1169-72. (Pubitemid 16002615)
28. Wenisch JM, Schmid D, Kuo HW, Allerberger F, Michl V, Tesik P, et al. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2012;56(4):1974-8.
29. Mattila J, Männistö PT, Mäntylä R, Nykänen S, Lamminsivu U. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob Agents Chemother. 1983;23(5):721-5. (Pubitemid 13087010)
30. Thiercelin JF, Diquet B, Levesque C, Ghesquiére F, Simon P, Viars P. Metronidazole kinetics and bioavailability in patients undergoing ganstrointestinal surgery. Clin Pharmacol Ther. 1984;35(4):510-9. (Pubitemid 14133492)
31. Kuriyama A, Jackson JL, Doi A, Kamiya T. Metronidazole-induced central nervous system toxicity: a systematic review. Clin Neuropharmacol. 2011;34(6):241-7.
32. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97(7):1769-75. (Pubitemid 34761404)
33. Gordi T, Khamis H. Simple solution to a common statistical problem: interpreting multiple tests. Clin Ther. 2004;26(5):780-6. (Pubitemid 38736968)
34. Summary basis of decision (SBD) for DIFICIDTM. Control number 151086. Ottawa (ON): Health Canada; 2012 Oct 30 [cited 2013 Nov 13]. Available from: www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2012-dificid-151086- eng.php
35. DIFICID® (fidaxomicin) [product monograph]. Toronto (ON): Optimer Pharmaceuticals Canada Inc; revised 2012 Jun 4.
36. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al.; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422-31.
37. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al.; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281-9.
38. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55 Suppl 2:S154-61.
39. New C. diff drug approved. The Canadian Press; 2012 Jul 5 [cited 2012 Aug 12]. Available from: www.thespec.com/print/article/755566
40. Ontario drug benefit formulary/comparative drug index. Toronto (ON): Ministry of Health and Long-Term Care; updated 2012 Aug 27 [cited 2012 Aug 31]. Available from: https://www.healthinfo.moh.gov.on.ca/formulary/index.jsp
41. Common drug review - notice of CDEC final recommendation: fidaxomicin. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2012 Dec 19.
42. Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomycin worth the cost? An economic analysis. Clin Infect Dis. 2013;57(4):555-61.
43. Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011;66(12):2850-5.
44. Pillai A, Nelson RL. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;(1):CD004611.
45. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271(24):1913-8. (Pubitemid 24177098)
46. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combine with Saccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012-7. (Pubitemid 32299362)
47. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol. 2005;54(Pt 9):905-6. (Pubitemid 41216291)
48. Wullt M, Hagslätt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis. 2003;35(6-7):365-7. (Pubitemid 37038627)
49. Johnston BC, Ma SS, Goldenberg JZ, Thorlund K, Vandvik PO, Loeb M, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med. 2012;157(12):878-88.
50. Friedman G. The role of probiotics in the prevention and treatment of antibiotic-associated diarrhea and Clostirdium difficile colitis. Gastroenterol Clin North Am. 2012;41(4):763-79.
51. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500-8.
52. Mattila E, Uusitalo-Seppälä R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142(3):490-6.
53. Midthun K. Letter to C. Richard Boland, American Gastroenterological Association. Rockville (MD): Department of Health and Human Services, Food and Drug Administration, Public Health Service; 2013 Apr 25 [cited 2013 Jun 27]. Available from: http://highroadsolution.com/file-upload-2/files/ fda+response+letter+to+fmt+inquiry.pdf
54. Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-15.